SSStewart Sell

Stewart Sell

*This is an algorithmically generated author record based on publicly available information.

Stewart Sell has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bona Fide Th17 Cells without Th1 Functional Plasticity Protect against Influenza

    by Kunal Dhume, Caroline M. Finn, Priyadharshini Devarajan, Ayushi Singh, Joanne D. Tejero, Emily Prokop, Tara M. Strutt, Stewart Sell, Susan L. Swain, Karl Kai McKinstry

    Optimal transcriptional programming needed for CD4 T cells to protect against influenza A virus (IAV) is unclear. Most IAV-primed CD4 T cells fit Th1 criteria. However, cells deficient for the Th1 “master regulator,” T-bet, although marked by reduced Th1 identity, retain robust protective capacity. In this study, we show that T-bet’s paralog, Eomesodermin (Eomes), is largely redundant in the presence of T-bet but is essential for the residual Th1 attributes of T-bet–deficient cells. Cells lacking both T-bet and Eomes instead develop concurrent Th17 and Th2 responses driven by specific inflammatory signals in the infected lung. Furthermore, the transfer of T-bet– and Eomes-deficient Th17, but not Th2, effector cells protects mice from lethal IAV infection. Importantly, these polyfunctional Th17 effectors do not display functional plasticity in vivo promoting gain of Th1 attributes seen in wild-type Th17 cells, which has clouded evaluation of the protective nature of Th17 programming in many studies. Finally, we show that primary and heterosubtypic IAV challenge is efficiently cleared in T-bet– and Eomes double-deficient mice without enhanced morbidity despite a strongly Th17-biased inflammatory response. Our studies thus demonstrate unexpectedly potent antiviral capacity of unadulterated Th17 responses against IAV, with important implications for vaccine design.


  • Open Access

    CD25-Targeted IL-2 Signals Promote Improved Outcomes of Influenza Infection and Boost Memory CD4 T Cell Formation

    by Fahmida Alam, Ayushi Singh, Valeria Flores-Malavet, Stewart Sell, Andrea M. Cooper, Susan L. Swain, K. Kai McKinstry, Tara M. Strutt

    IL-2 is a pleotropic cytokine with potent pro- and anti-inflammatory effects. These divergent impacts can be directed in vivo by forming complexes of IL-2 and anti–IL-2 mAbs (IL-2C) to target IL-2 to distinct subsets of cells based on their expression of subunits of the IL-2R. In this study, we show that treatment of mice with a prototypical anti-inflammatory IL-2C, JES6-1–IL-2C, best known to induce CD25+ regulatory CD4 T cell expansion, surprisingly causes robust induction of a suite of inflammatory factors. However, treating mice infected with influenza A virus with this IL-2C reduces lung immunopathology. We compare the spectrum of inflammatory proteins upregulated by pro- and anti-inflammatory IL-2C treatment and uncover a pattern of expression that reveals potentially beneficial versus detrimental aspects of the influenza-associated cytokine storm. Moreover, we show that anti-inflammatory IL-2C can deliver survival signals to CD4 T cells responding to influenza A virus that improve their memory fitness, indicating a novel application of IL-2 to boost pathogen-specific T cell memory while simultaneously reducing immunopathology.


  • Open Access

    Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty

    by Stewart Sell, Zoran Ilic

    Differentiation therapy is directed to the self-renewing cancer stem cells, as well as their progeny transit amplifying cells, to force them to mature to terminal differentiation. Differentiation therapy is effective in treatment of neuroblastomas and myeloid leukemias. Checkpoint inhibition therapy removes blocks to cancer reactive T-killer cells and allows them to react to malignant cells and limit the growth of cancer. The percentage of patients with a given cancer that responds to either therapy is less than hoped for, and the duration of response is variable. Multiplying the response rate (percentage of patients responding to therapy) by the duration of response may be used to derive a survival score for patients treated with differentiation therapy or checkpoint inhibition. By this criterion, differentiation therapy gives better survival scores than checkpoint inhibition. Yet, checkpoint inhibition is considered a great success, mostly because it may be applied to many different types of cancer, and differentiation therapy is considered relatively ineffective because it is limited to a few specific cancers. On the other hand, the cost of checkpoint inhibition treatment is 10–20 times more per patient than that of differentiation therapy. Hopefully, future combined treatments and advances in both approaches will increase the effectiveness of these cancer treatments.


  • T-bet optimizes CD4 T-cell responses against influenza through CXCR3-dependent lung trafficking but not functional programming

    by Kunal Dhume, Caroline M. Finn, Tara M. Strutt, Stewart Sell, K. Kai McKinstry


  • Open Access

    Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice

    by Dana R. Crawford, Zoran Ilic, Ian Guest, Ginger L. Milne, John D. Hayes, Stewart Sell

    We recently generated glutathione S-transferase (GST) A3 knockout (KO) mice as a novel model to study the risk factors for liver cancer. GSTA3 KO mice are sensitive to the acute cytotoxic and genotoxic effects of aflatoxin B1 (AFB1), confirming the crucial role of GSTA3 in resistance to AFB1. We now report histopathological changes, tumor formation, biochemical changes and gender response following AFB1 treatment as well as the contribution of oxidative stress. Using a protocol of weekly 0.5 mg AFB1/kg administration, we observed extensive oval (liver stem) cell (OC) proliferation within 1–3 weeks followed by microvesicular lipidosis, megahepatocytes, nuclear inclusions, cholangiomas and small nodules. Male and female GSTA3 KO mice treated with 12 and 24 weekly AFB1 injections followed by a rest period of 12 and 6 months, respectively, all had grossly distorted livers with macro- and microscopic cysts, hepatocellular nodules, cholangiomas and cholangiocarcinomas and OC proliferation. We postulate that the prolonged AFB1 treatment leads to inhibition of hepatocyte proliferation, which is compensated by OC proliferation and eventually formation of cholangiocarcinoma (CCA). At low-dose AFB1, male KO mice showed less extensive acute liver injury, OC proliferation and AFB1-DNA adducts than female KO mice. There were no significant compensatory changes in KO mice GST subunits, GST enzymatic activity, epoxide hydrolase, or CYP1A2 and CYP3A11 levels. Finally, there was a modest increase in F2-isoprostane and isofuran in KO mice that confirmed putative GSTA3 hydroperoxidase activity in vivo for the first time.


  • Open Access

    Immunopathology of Experimental Models of Syphilis, Influenza, and Asthma

    by Stewart Sell

    The introduction of immunopathologic reaction classification in the 1960s led to a major advance in understanding immune effector mechanisms and how lesions of immunopathologic diseases developed. In this article, immunopathologic mechanisms are presented for experimental models of syphilis, influenza, and asthma. The chancre of syphilis is a delayed hypersensitivity skin reaction that is initiated by sensitized T cells that activate macrophages to phagocytose and kill the infecting organism, Treponema pallidum, in interstitial tissues. The primary immune effector mechanism in experimental influenza is T-cell−mediated cytotoxicity that kills infected epithelial cells, bronchial lining cells, and Type-II pneumocytes, in a manner similar to viral exanthema. The bronchial lesions of the experimental model of asthma in mice are preceded by an immune complex vasculitis and not an immunoglobulin E−mediated mast cell mechanism.


  • Open Access

    Genetic or Pharmacologic Activation of Nrf2 Signaling Fails to Protect Against Aflatoxin Genotoxicity in Hypersensitive GSTA3 Knockout Mice

    by Kevin H. Kensler, Stephen L. Slocum, Dionysios V. Chartoumpekis, Patrick M. Dolan, Natalie M. Johnson, Zoran Ilic, Dana R. Crawford, Stewart Sell, John D. Groopman, Thomas W. Kensler, et al.

    Mice are resistant to aflatoxin hepatotoxicity, primarily due to high expression of glutathione S-transferases (GSTs), and in particular the GSTA3 subunit. Nuclear factor erythroid 2 related factor 2 (Nrf2) signaling, which controls a broad-based cytoprotective response, was activated either genetically or pharmacologically in an attempt to rescue GSTA3 knockout mice from aflatoxin genotoxicity. Genetic activation of Nrf2 signaling was attained in a GSTA3: hepatocyte-specific Keap1 double knockout (DKO) mouse whereas pharmacologic activation of Nrf2 was achieved through pretreatment of mice with the triterpenoid 1-[2-cyano-3-,12-dioxoleana-1,9(11)-dien-28-oyl] imidazole (CDDO-Im) prior to aflatoxin B1 exposure. Following oral treatment with aflatoxin, urine was collected from mice for 24 h and hepatic and urinary aflatoxin metabolites then quantified using isotope dilution-mass spectrometry. Although Nrf2 was successfully activated genetically and pharmacologically, neither means affected the response of GSTA3 knockout mice to chemical insult with aflatoxin. Hepatic aflatoxin B1-N7-guanine levels were elevated 120-fold in GSTA3 knockout mice compared with wild-type and levels were not attenuated by the interventions. This lack of effect was mirrored in the urinary excretion of aflatoxin B1-N7-guanine. By contrast, urinary excretion of aflatoxin B1-N-acetylcysteine was >200-fold higher in wild-type mice compared with the single GSTA3 knockout or DKO mouse. The inability to rescue GSTA3 knockout mice from aflatoxin genotoxicity through the Nrf2 transcriptional program indicates that Gsta3 is unilaterally responsible for the detoxication of aflatoxin in mice.


  • Tumor Immunity

    by Stewart Sell

    A short history of tumor immunology is presented in this chapter. Although the evidence for tumor-specific transplantation antigens accumulated in experimental models, tumor-specific immunity in humans remained controversial. Some human tumors have tumor antigens detectable by in vitro assays. Several human tumor-specific antigens have been identified by these assays. Therefore, most of the data in which in vitro human tumor immunity was tested using cell lines is now being reinterpreted. If the immune system is playing a prominent role in the development of cancers, then agents that cause cancer (carcinogens) would be expected to be immunosuppressive, and immunosuppressive agents would be expected to be carcinogenic. Tumor tissue is often infiltrated by large numbers of lymphocytes, perhaps because of a cellular immunologic reaction to tumor antigens. Properties of cells mediating tumor immunity, and the major oncogenes and their products under study as determinants of prognosis in human cancer are listed. More recently, new tumor antigens identified both serologically (SEREX) and by reactivity of cell lines from patients to tumors, genetically modified cells expressing these antigens, as well as a variety of adjuvants, including liposomes, cytokines, conjugates, viral vectors, bacillus Calmette-Guérin (BCG), and dendritic cell processing, are now being tested in clinical trials. Understanding and control of these phenomena may result in effective immunotherapy of cancer in humans. The chapter ends with the history of immunotherapy of cancer.

  • Immunology, Immunopathology, and Immunity

    by Stewart Sell

    The sixth edition of this best-selling textbook presents a systematic account of the effects, both good and bad, of the immune system. Special emphasis is placed on what the immune system actually does in causing and preventing disease. Divided into two parts, the sixth edition discusses inflammation, the fundamentals of the immune system and how it is activated, the seven immune effector mechanisms, and how these effector mechanisms act not only to protect against infection and cancer but also to cause diseases. Valuable reading for physicians, medical students, graduate students, nurse practitioners, physician assistants, teachers of immunology, and advanced courses in immunology. Electronic Only, 753 pages, illustrations, index.


  • An Introduction to Cancer Markers and Cytogenetics

    by Sandra R. Wolman, Stewart Sell, Eric Wolman